Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach

Combination antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) infection is one of the most important advances in medicine in the past quarter century. The availability of several single-tablet multidrug treatment regimens that effectively control the replication of HIV type 1 (HIV-1) has dramatically improved the prognosis of people living with HIV who are able to adhere to daily oral therapy. Now two pivotal international, phase 3, randomized trials — Antiretroviral Therapy as Long Acting Suppression (ATLAS) and First Long-Acting Injectable Regimen (FLAIR), the results of which are reported in the Journal1,2 — show 48-week outcomes among . . .